TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
WHO launches genetic research register after designer-baby scandal
The WHO announced it will create a global registry to track research into human genetic manipulation, after a call to halt all work on germline genome editing -- used in China last year to genetically modify twin baby girls.
Change Size
The WHO announced it will create a global registry to track research into human genetic manipulation, after a call to halt all work on germline genome editing -- used in China last year to genetically modify twin baby girls. (Shutterstock/Liudmila Fadzeyeva)
T
he WHO announced Thursday it will create a global registry to track research into human genetic manipulation, after a call to halt all work on germline genome editing -- used in China last year to genetically modify twin baby girls.
"New genome editing technologies hold great promise and hope for those who suffer from diseases we once thought untreatable," the World Health Organization's Director General for told the body's genome editing oversight committee meeting in Geneva.
"But some uses of these technologies also pose unique and unprecedented challenges -– ethical, social, regulatory and technical,” he added.
Chinese scientist He Jiankui's announcement last November that he had altered the DNA of twins girls in southern China by using molecular scissors -- ostensibly to prevent them from contracting HIV.
He was then fired from his university, put under police investigation and ordered to halt his work.
Read also: Designer babies: Moratorium on genome editing needed, say experts
But his announcement provoked a global backlash from scientists saying the untested procedure was unethical and potentially dangerous and in December the WHO set up an expert committee to look into the matter.
About 30 nations currently have legislation directly or indirectly barring all clinical use of germline editing.
WHO chief Tedros Adhanom Ghebreyesus emphasised that countries should not allow any further work on human germline genome editing "until the technical and ethical implications have been properly considered", the WHO said in a statement.
Accepting the recommendation of its 18-member expert committee, WHO announced plans for an initial phase of the registry to include both germline and somatic clinical trials
Somatic mutations occur in a single body cell and cannot be inherited while germline mutations can be passed onto offspring.
